Whole-body 18f-fdg pet for the evaluation of patients with hodgkin's disease and non-hodgkin's lymphoma

Nuclear Medicine Communications

Volumn 20, Issue 1, 1999, Pages 13-20

  Jerusalem, G ^a   Warland, V ^a   Najjar, F ^a   Paulus, P ^a   Fassotte, M F ^a   Fillet, G ^a   Rigo, P ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; RADIATION ATTENUATION; ADOLESCENT; BONE MARROW; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIGESTIVE SYSTEM; FOLLOW UP; LIVER; LYMPH NODE; MIDDLE AGED; SCINTISCANNING; SPLEEN; WHOLE BODY COUNTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; DIGESTIVE SYSTEM; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; LIVER; LYMPH NODES; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; NEOPLASM STAGING; SPLEEN; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; WHOLE-BODY COUNTING;

EID: 0032587391     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199901000-00004     Document Type: Article

References (24)

1. Warburg O, Wind F, Neglers E. On the metabolism of tumors in the body. In: Warburg O, ed. Metabolism of tumors. London: Constable, 1930: 254-270.
2. Weber G. Enzymology of cancer cells. New Engl J Med 1977; 296: 486-551.
3. Wahl RL. Positron emission tomography: Application in oncology. In Murray ICP, Ell PJ, eds. Nuclear medicine, clinical diagnosis and treatment. London: Churchill Livingstone, 1995: 801-820.
4. Rigo P, Paulus P, Kaschten BJ et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-1674.
5. Conti PS, Lilien DL, Hawley K., et al. PET and (18F)-FDG in oncology: A clinical update. Nucl Med Biol 1996; 23: 717-735.
6. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-(F-18)-Fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology 1994; 190: 111-116.
7. Moog F, Bangerter M, Diederichs CG et al. Lymphoma: Role of whole-body 2-deoxy-2-(F-18) fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 302: 795-800.
8. Huh CK, Glaspy J, Rosen P et al. Whole-body FDG-PET imaging for staging of Hodgkin’s disease and lymphoma. J Nucl Med 1997; 38: 343-348.
9. Schönberger JA, Stollfuss JC, Kocher F. Whole-body 18-FDG-PET for staging of malignant lymphomas. Eur J Nucl Med 1994; 21: 727.
10. Lapela M, Leskinen S, Minn HRI et al. Increased glucose metabolism in untreated non-Hodgkin’s lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995; 86: 3522-3527.
11. Leskinen-Kallio S, Ruot Salainen U, Nagren K., et al. Uptake of carbon-II-methionine and fluorodeoxyglucose in non-Hodgkin’s lymphoma: A PET study. J Nucl Med 1991; 32: 1211-1218.
12. Rodriguez M, Rehn S, Ahlström H et al. Predicting malignancy grade with PET in non-Hodgkin’s lymphoma. J Nucl Med 1995; 36: 1790-1796.
13. Okada J, Yoshikawa K, Imazeki K et al. The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis. J Nucl Med 1991; 32: 686-691.
14. Hoekstra OS, Ossenkoppele GJ, Golding R et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993; 34: 1706-1710.
15. de Wit M, Bumann D, Beyer W et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8 (suppl. I): S57-S60.
16. Okada J, Oonishi H, Yoshikawa K et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994; 8: 187-191.
17. Price P, Jones T, on behalf of the EC PET Oncology Concerted Action and the EORTC PET Study Group. Can positron emission tomography be used to detect subclinical response to cancer therapy? Eur J Cancer 1995; 31A: 1924-1927.
18. Hagemeister FB, Fesus SM, Lamki LM, Haynie TP. Role of the gallium scan in Hodgkin’s disease. Cancer 1990; 65: 1090-1096.
19. Anderson KC, Leonard RCF, Canellos GP et al. High-dose gallium imaging in lymphoma. Am J Med 1993; 75: 327-331.
20. Fishman EK, Kuhlman JE, Jones RJ. CT of lymphoma: Spectrum of disease. Radiographics 1991; 11: 647-669.
21. Barrington SF, Saunders CAD, Madan R et al. Can FDG-PET predict bone marrow involvement in patients with lymphoma? J Nucl Med 1997; 38 (suppl.): 128P.
22. Karp JS, Muehllehner G, Qu H, Yan XH. Singles transmission in volume-imaging PET with a 137Cs source. Phys Med Biol 1995; 40: 929-944.
23. Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body FDG-PET post-treatment evaluation in Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL) has higher diagnostic and prognostic value than classical CT-scan imaging. Blood 1997; 90: 336a.
24. Jerusalem G, Beguin Y, Fassotte MF et al. Early assessment of response to chemotherapy by FDG-PET is highly predictive of outcome in patients with high-grade non-Hodg-kin’s lymphoma (NHL). Blood 1997; 90: 388a.